United Therptcs Free of FREEDOM

Tags: uthr
21 Nov 4:18am
Posted by ZacksResearch
0 Comments
Read original blog entry

United Therapeutics Corporation (UTHR), a biotechnology company, engages in the development and commercialization of therapeutic products for patients with chronic and life-threatening diseases. It offers products primarily in three therapeutic areas, including cardiovascular, cancer and infectious diseases.

We were rightfully bearish on United heading into the FREEDOM-C data earlier in the week. The trial failed, as we predicted it would. Oral Remodulin seems unlikely before 2012. However, thanks to a quick deal with Eli Lilly & Co. (LLY), United will move into the oral PAH [pulmonary arterial hypertension] market sooner than expected with Cialis.

Therefore, with the biggest hiccup now past, and upside potentially coming next year, United Therapeutics no longer looks like a Sell. Our rating is now Hold.

Read the full analyst report on UTHR

Read the full analyst report on LLY



Get real-time market insights and profitable stock recommendations from the team of analysts at Zacks Equity Research. See all today’s Analyst Blog entries on Zacks.com.

Comments

Back to top

Post comment

Back to top

Post a comment

Please login to post a comment

About

ZacksResearch

Zacks Investment Research is one of the most highly regarded firms in the investment industry. Our firm has long believed that that quantitative models (like the Zacks Rank) can predict stock prices more accurately than individual analysts. However we also recognize that models are most effective when they are employed by analysts who have deep fundamental knowledge of the company and its industry. Consequently Zacks Equity Research combines Zacks quantitative models with the insight provided by an experienced team of 50 analysts to create superior long term stock recommendations. Discover all their timely insight and recommendations daily on Zacks.com.

Recent Entries